cGxP.wire https://validator.w3.org/feed/docs/rss2.html Compass Pathways Launches Change the Tune in TRD Nanobiotix Advances JNJ-1900 in Recurrent NSCLC Pulse Biosciences Completes PRECISE-BTN Enrollment Syntis Bio Advances Oral SYNT-101 Toward Phase 2 Rocket Pharmaceuticals Advances RP-A501 Toward Danon Disease Approval One04 Therapeutics Launches With CPV-104 Clinical Expansion ENA Respiratory Advances INNA-051 Into Part B Phase IIa Acurx Pharmaceuticals Presents Ibezapolstat C. difficile Data QurCan Therapeutics and Lilly Advance Nucleic Acid Therapies Ocular Therapeutix Advances AXPAXLI Toward Wet AMD NDA Elanco Advances Pet Health Innovation as Tick Season Expands Summit Therapeutics Reports Ivonescimab Survival Data at WCLC Connect Biopharma Advances Rademikibart Toward Phase 3 PolarityBio Gains FDA Priority Review for SkinTE in DFUs Novo Nordisk Launches Novo Rebrand and New Corporate Culture Telix Gains FDA Approval for Pixclara in Glioma Imaging Pharmazz Gains FDA Orphan Designation for Sovateltide in NHIE Corbus Advances CRB-913 Toward Phase 2 in Obesity Debut Develops Biotech Ingredient for Hyperpigmentation Care Castle Biosciences Shows TissueCypher Improves Barrett’s Care Nasus Pharma Advances NS002 Toward Pivotal Anaphylaxis Study Eli Lilly to Present New Cardiometabolic Data at EASD 2026 Taiho Oncology’s Zipalertinib Improves PFS in EGFR Lung Cancer Lundbeck Completes Enrollment in Phase III Dravet Trial Organon’s MIUDELLA FDA Review Advances Hormone-Free IUD GSK to Acquire Chimagen TCE for Multiple Myeloma Inductive Bio Launches Indy AI Assistant for Drug Discovery Abbott Resolves 2022 Infant Formula Claims Through DOJ Deal Accro Bioscience Advances Rare Disease Drug Development Aignostics Launches PathoSearch for AI-Driven Pathology Case Consano Bio Announces Peer-Reviewed Nonclinical Research Supporting Therapeutic Potential of C-1101 in Chronic Sciatica Whitehawk Therapeutics’ PTK7 Data Support ADC Development Telomir Advances Telomir-Zn in Human and Canine Osteosarcoma Bright Path Labs Receives FDA AMT Designation for Medicines Armata’s AP-SA02 Receives FDA Breakthrough Designation Evaxion Expands AI-Immunology Platform Into Autoimmune Disease Santa Ana Bio Advances SAB01 Into Phase 1 Tris Pharma Expands QuilliChew ER With 30-Count Bottle Tenaya Therapeutics Gains RMAT Designation for TN-401 Sanofi and Cheplapharm Form Strategic Mature Medicines Partnership Biofrontera Gains FDA Approval for Ameluz in Basal Cell Carcinoma Revolution Medicines Gains FDA Breakthrough Designation for RASONQUE Sionna Advances SION-451 and SION-2222 Into Phase 2a Agomab Advances AGMB-447 Into Phase 2 for IPF J&J’s RYBREVANT Shows Longest OS in EGFR Lung Cancer AbelZeta’s C-CAR168 Receives FDA IND Clearance Curium Gains FDA Approval for BEXLUTRY in GEP-NETs TuHURA’s TBS-2025 Receives FDA IND Clearance for AML Clearmind Medicine Advances CMND-100 Into AUD Clinical Trial Quantum BioPharma Advances Lucid-MS Toward Phase 2 in MS